Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET phase II trial of tirofiban plus alteplase in acute ischemic stroke
CTR20213126Phase 2Active
- Sponsor
- Grand Pharmaceutical Group
- Start
- Dec 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Tirofiban + alteplase with Placebo + alteplase (2 arms). Primary endpoints: Symptomatic intracranial hemorrhage within 48 hours, Modified Rankin Scale 0 to 1 at day 90 and 1 more. Started Dec 2021; status: active.
02
Drugs
tirofibantissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20213126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213126.